Login to Your Account



NEWS & VIEWS

Macrogenics' Koenig talks DART deals, growing pipeline


Friday, July 25, 2014

In the past four years, Macrogenics Inc. has inked five lucrative big pharma partnerships for its bispecific and multispecific antibody platform, most recently a potential $469 million deal with Takeda Pharmaceutical Co. Ltd.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription